razoxane

Razoxane is an orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA). It exhibits antineoplastic (anticancer), antiangiogenic (inhibiting new blood vessel formation), and antimetastatic activities. Mechanistically, razoxane acts as a type II DNA topoisomerase inhibitor without inducing DNA strand breaks. This inhibition disrupts DNA synthesis and cell division during premitotic and early mitotic phases of the cell cycle. Additionally, it has been shown to block entry of cultured human lymphocytes into mitosis and arrest dividing cells in prophase and early metaphase. Beyond oncology indications such as soft tissue sarcoma (now discontinued), razoxane has also been used in the systemic treatment of psoriasis[1][3][5][7].

Brand names

RazoxinTepironeTroxozone

Other names

razoxaneRazoxanumRazoxana(+/-)-1,2-Bis(3,5-dioxopiperazinyl)propane1,2-Bis(3,5-dioxo-1-piperazinyl)propane